GlassScriptPhysician profile
Cynthia J Kaylor
NPI 1174573299
$5,377.16
in general payments reported to CMS, 2019-2025
34 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $768 · 2022: $945 · 2023: $1,350 · 2024: $1,109 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,663.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,258.54 | 2021-2025 | |
| Amgen INC. | $793.99 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $353.34 | 2021-2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $298.00 | 2021-2024 | Xarelto |
| Pfizer INC. | $293.14 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $287.13 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $241.25 | 2021-2025 | Watchman Flx, Watchman Access System |
| Edwards Lifesciences Corporation | $224.25 | 2021-2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $220.15 | 2021-2025 | Verquvo, Capvaxive, Lagevrio |
| Medtronic, INC. | $161.28 | 2021-2024 | Micra |
| Scpharmaceuticals INC. | $116.49 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.06 | 2022-2023 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $101.45 | 2021-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $101.18 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $92.57 | 2022-2025 | Evkeeza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $91.58 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.99 | 2021-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $55.65 | 2022-2024 | |
| Amarin Pharma, INC. | $53.88 | 2022 | |
| Corcept Therapeutics | $51.43 | 2025 | Korlym |
| Novo Nordisk INC | $41.89 | 2023-2024 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $41.13 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $40.91 | 2021-2023 | Uptravi, Opsumit |
| Angiodynamics, INC. | $35.85 | 2025 | Alphavac |
| Irhythm Technologies, INC. | $34.65 | 2024 | Zio Monitor, Zio Xt Patch |
| Abbott Laboratories | $34.56 | 2021-2025 | Navitor |
| Bridgebio Pharma, INC. | $32.95 | 2025 | Attruby |
| Abiomed | $30.29 | 2022 | |
| Genzyme Corporation | $24.27 | 2022 | |
| Glaxosmithkline, LLC. | $20.16 | 2025 | Nucala |
| Alnylam Pharmaceuticals INC. | $19.07 | 2021 | |
| Inspire Medical Systems, INC. | $17.47 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $12.60 | 2021 | |
| Abbvie INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Kaylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.